Sage Therapeutics Inc. leadership overhyped prospects for three neurological and psychiatric treatments, harming the biopharmaceutical company’s repute and wallet, a shareholder lawsuit said.

COPD cases are rising in women. Uncover the latest insights to enhance diagnosis and treatment in your women patients.

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate of $3.32. Earnings declined 18% year over year on a reported basis, owing ...

Detailed price information for Sage Therapeutic Com (SAGE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Sage Therapeutic Com (SAGE-Q) from The Globe and Mail including charting and trades.

SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1. ...

Sage Therapeutics and partner Biogen equally share profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan ...

--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (SAGE), today reported ... Collaboration revenue represents 50% of the net revenue recorded when Biogen ships ZURZUVAE to the distributors.